Media - News Articles and Press Releases

LSP Bio launches RenehaVis™ and SportVis™ in the UK

Two new and innovative treatments for osteoarthritis of the knee and injuries of the ankle and elbow relieve pain, provide rapid and long-lasting benefit, and offer value for healthcare budgets.

Read the article here.

RenehaVis™ and SportVis™ to be listed in the UK Drug Tariff

NHS confirm that SportVis™ and RenehaVis™ will be listed in the UK Drug Tariff from April 2012.

Read the RenehaVis™ and SportVis™ articles here.

RenehaVis™ 12 month efficacy data approved in SPC update

LSP Bio confirm RenehaVis™ efficacy has been formally extended from 4 to 12 months for one treatment.

Read the RenehaVis™ article here.